Wall Street Refuses to Blink: 2 Healthcare Stocks at 52-Week Lows That Analysts Still Love

• Both Abbott Laboratories (ABT) and Boston Scientific (BSX) trade at or near 52-week lows while Wall Street analysts remain overwhelmingly bullish.

• Boston Scientific’s unanimous analyst backing and stronger earnings momentum represent a more concentrated setup, though both carry execution risk at current prices.

• The analyst who called NVIDIA in 2010 just named his top 10 AI stocks. Get them here FREE.

Boston Scientific (NYSE: BSX) trades around $61, with analyst price targets ranging from $69 (conservative) to $124 (optimistic), implying substantial upside. Abbott Laboratories (NYSE: ABT) trades near $95 against an optimistic target of $143. Both trade at or near 52-week lows while Wall Street analysts maintain bullish ratings.

Boston Scientific makes cardiovascular devices, endoscopy tools, and neuromodulation systems. Abbott spans medical devices, diagnostics, nutrition, and pharmaceuticals. Both benefit from an aging global population requiring more cardiac procedures, glucose monitoring, and cancer diagnostics. Healthcare spending has grown to $5.9 trillion annually as of February 2026, up from $5.6 trillion in January 2025. This structural tailwind makes the price declines difficult to justify on fundamentals alone.

Boston Scientific has declined 35.5% year-to-date, trading just above its 52-week low of $60.05, compared to a 52-week high of $109.50. The sell-off accelerated after Q4 2025 earnings when litigation-related net charges of $194 million reduced GAAP EPS below guidance and tariff headwinds of approximately $200 million were absorbed in 2025. Macro anxiety about trade policy and device manufacturing costs intensified the decline. The stock dropped from roughly $104.79 at the Q3 2025 filing to $77.61 at the Q4 2025 filing.

READ: The analyst who called NVIDIA in 2010 just named his top 10 AI stocks

Abbott’s decline has been steadier but nearly as painful, down 24.5% year-to-date and sitting just above its 52-week low of $93.92. GAAP operating income fell 20.32% year-over-year in Q1 2026, weighed down by the $21 billion Exact Sciences acquisition completed March 23, 2026, which carries approximately $0.20 per share in dilution for 2026. The Nutrition segment fell 6.0% to $2.02 billion as consumers resisted years of price increases. The S&P 500 has also struggled in 2026, but neither stock has found support in any market stabilization.

On Boston Scientific, the analyst community is unified. The consensus stands at 10 Strong Buy, 22 Buy, one Hold, zero Sell, and zero Strong Sell across 33 analysts. The bull case rests on the FARAPULSE pulsed field ablation platform, which drove cardiovascular segment growth of 18.2% to $3.48 billion in Q4 2025. Organic growth reached 12.7% in Q4, within and at the top end of the company’s own guidance range of 11% to 13%. Management guided 2026 adjusted EPS of $3.43 to $3.49, up from the full-year 2025 actual of $3.06. Analysts see double-digit growth while the stock price implies stagnation or decline.

Abbott’s analyst support is nearly as strong. Six analysts rate it Strong Buy, 16 rate it Buy, six rate it Hold, and none rate it Sell or Strong Sell. Medical Devices grew 13.2% to $5.54 billion in Q1 2026, and the CGM franchise saw FreeStyle Libre sales reached $2.08 billion, up 13.8%. The Exact Sciences acquisition adds fast-growing oncology diagnostics. CEO Robert Ford said the deal is “further strengthening our confidence in delivering accelerating growth as we move through the year.” Abbott has raised its dividend for 54 consecutive years, signaling management views current pressure as temporary.

Again, Boston Scientific’s case for recovery rests on whether FARAPULSE continues gaining share in cardiac ablation and tariff headwinds prove manageable. The earnings beat streak and unanimous analyst conviction at a 52-week low is rare. The risk case centers on whether litigation charges and tariff costs are structural, as the stock would need multiple expansion alongside earnings growth to reach even conservative targets.

Abbott’s recovery thesis depends on whether Exact Sciences integration stays on track and Medical Devices sustains double-digit growth through 2026. The Dividend Aristocrat status and 54-year increase streak reflect management’s confidence in the long-term outlook. Key risks include Nutrition weakness deepening, CGM competition intensifying beyond expectations, or acquisition costs exceeding guidance of $0.20 dilution.

Wall Street is pouring billions into AI, but most investors are buying the wrong stocks. The analyst who first identified NVIDIA as a buy back in 2010 — before its 28,000% run — has just pinpointed 10 new AI companies he believes could deliver outsized returns from here. One dominates a $100 billion equipment market. Another is solving the single biggest bottleneck holding back AI data centers. A third is a pure-play on an optical networking market set to quadruple. Most investors haven’t heard of half these names. Get the free list of all 10 stocks here.